Chemkart India Limited company name has completed a ₹1.00 crore investment in its wholly owned subsidiary, Easy Raw Materials Private Limited, through a rights issue. The transaction involves the allotment of 10,00,000 equity shares at an issue price of ₹10 each, which is equal to the face value. This capital injection is designated for the commissioning of the subsidiary’s manufacturing unit, adhering to the objects of the initial public offer prospectus dated July 10, 2025.

The disclosure was made to the Bombay Stock Exchange on August 8, 2026, under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing cites Regulation 30(6) read with Schedule III Part A Para A (1) of the SEBI LODR Regulations, as amended. Additionally, the company referenced circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the required details of the transaction.

Transaction Details

The investment was executed via cash consideration. Chemkart India acquired 10,00,000 equity shares with a face value of ₹10 each. The total consideration paid was ₹1.00 crore. As Easy Raw Materials Private Limited is a wholly owned subsidiary, the pre-allotment shareholding of Chemkart India was 100.00%, and it remains 100.00% post-allotment. The transaction is classified as a related party transaction but was conducted at arm’s length. No governmental or regulatory approvals were required for this acquisition.

Subsidiary Financial Position

Easy Raw Materials Private Limited, incorporated in 2020, operates in the trading of pharma products and nutritional supplements. The subsidiary’s authorized share capital stands at ₹10,00,00,000, divided into 1,00,00,000 equity shares of ₹10 each. Following the recent allotment, the paid-up share capital is ₹8,51,00,000, comprising 85,10,000 equity shares.

As of March 31, 2026, the subsidiary reported a turnover of NIL. It recorded a loss after tax of ₹59.47 lakhs and a net worth of ₹578.60 lakhs. The turnover for the last three years has been NIL, indicating that the entity is in the pre-revenue phase ahead of the manufacturing unit commissioning funded by this investment.

Chemkart India Ltd reported revenue from operations of ₹99.60 crore for the period from April to June 2026 (Q1FY27). The company achieved nearly 50% of the previous financial year's full-year revenue in the first three months, alongside improved margins. This performance demonstrates rapid yet disciplined growth, providing strong momentum for the remainder of the financial year.

Ankit Mehta, Chairman & Managing Director, attributed the results to steady execution and the team's focus on building sustainable growth. He highlighted that the figures reflect a consistent build-up of sourcing capabilities, supplier relationships, and quality systems over time.

Strategic Developments

A key milestone during the period was achieved by the company's subsidiary, Vinstar Biotech Private Limited. It received trial orders from multiple customers for value-added ingredients developed in-house. This development validates the group's research and development capabilities and marks its transition from a supplier of ingredients to a developer of proprietary formulations.

The company is also investing in research and development to evolve into a complete solutions provider. This shift involves moving beyond product sales to offering customized solutions, including ingredient selection, application support, and formulation guidance. This transition is designed to deepen customer relationships and improve margin quality.

Manufacturing Expansion

Progress continued at the manufacturing facility under Easy Raw Materials Private Limited (EZRM). The project remains within its planned timeline, with civil work progressing as per schedule. Key milestones achieved during the period include the completion of plinth-level construction for Unit-1 and the receipt of the electricity sanction letter. Additionally, packaging machinery has been finalized, with delivery expected within 30-35 days of the purchase order release.

Operational Highlights

The company expanded its global supplier network and strengthened partnerships across key sourcing regions, with a specific focus on nutraceuticals. Chemkart also participated in three key industry exhibitions across India and Europe, including Vitafoods Europe in Barcelona, AAHAR in India, and Vitafoods India, to engage existing customers and build new relationships.